Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IPH2101 combined to lenalidomide · 1 trial · 2 indications
safety of IPH2101 combined with lenalidomide at different dose levels.
| Arm | Type | Description |
|---|---|---|
| IPH2101 and lenalinomide | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| IPH2101 combined to lenalidomide | DRUG | Dose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD) |
Inclusion Criteria: 1. Signed informed consent obtained before any trial-related activities 2. Progressive disease or relapse of multiple myeloma (according to the IMWG definition) after one or two prior therapeutic treatments or regimens for multiple myeloma that achieved a response duration of at...
IPH2101 combined with lenalidomide is an investigational combination therapy being studied in patients with multiple myeloma who are experiencing a first or second relapse. It pairs IPH2101, a small molecule KIR inhibitor, with lenalidomide, and was evaluated in a single Phase 1 clinical trial conducted in the United States.
IPH2101 combined with lenalidomide is being studied for the treatment of patients with multiple myeloma experiencing a first or second relapse. The combination was evaluated in a Phase 1 trial that enrolled 15 patients. It is an investigational regimen and is not an approved treatment for multiple myeloma.
IPH2101 targets KIR2DL3 and KIR2DL1, which belong to the killer cell immunoglobulin-like receptor family. It acts as an inhibitor of these targets. By targeting KIR2DL1 and KIR2DL3, IPH2101 is designed to modulate inhibitory signaling in natural killer cells, and it was studied in combination with lenalidomide.
IPH2101 combined with lenalidomide is being developed by Innate Pharma S.A., which trades under the ticker IPHA. The company sponsored the Phase 1 study evaluating the combination in patients with multiple myeloma experiencing a first or second relapse.
IPH2101 combined with lenalidomide is in Phase 1 development. The single Phase 1 trial evaluating the combination has been completed, and no active trials of this combination are ongoing. It is an investigational regimen and has not been approved by the FDA for any indication.
IPH2101 combined with lenalidomide was evaluated in clinical trial NCT01217203, titled a study on the safety, anti-tumor activity and pharmacology of IPH2101 combined with lenalidomide in patients with multiple myeloma experiencing a first or second relapse. The Phase 1 trial enrolled 15 patients in the United States and is completed.